Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation.

This article discusses the effects of benralizumab, a medication used to treat severe eosinophilic asthma, on basophils, a type of white blood cell. The study found that benralizumab reduced the percentage and activation of basophils in patients with severe eosinophilic asthma. The medication did not cause basophil degranulation or promote allergic reactions. Additionally, the study identified changes in the miRNA profile of basophils after benralizumab treatment. These findings suggest that benralizumab may have a dual benefit in reducing both eosinophils and basophils in patients with severe eosinophilic asthma. [Extracted from the article]